Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Yoshinobu Namba"'
Autor:
Daisuke Hazama, MD, PhD, Kenji Nakahama, MD, PhD, Hiroaki Kodama, MD, Akito Miyazaki, MD, Koichi Azuma, MD, PhD, Yosuke Kawashima, MD, Yuki Sato, MD, Kentaro Ito, MD, Yoshimasa Shiraishi, MD, Keita Miura, MD, Takayuki Takahama, MD, PhD, Satoshi Oizumi, MD, PhD, Yoshinobu Namba, MD, Satoshi Ikeda, MD, PhD, Hiroshige Yoshioka, MD, PhD, Asuka Tsuya, MD, PhD, Yuichiro Yasuda, MD, PhD, Yoshiki Negi, MD, PhD, Ayako Hara, MD, Michihito Toda, MD, PhD, Motoko Tachihara, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 1, Pp 100613- (2024)
Introduction: Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of lung cancer associated with poor prognosis and resistance to conventional chemotherapy. Immune checkpoint inhibitors (ICIs), alone or in combination with chemotherapy, were foun
Externí odkaz:
https://doaj.org/article/ceb8623f26cd4608b0d8ffd019ba6537
Autor:
Yuichiro Ohe, Yoshinobu Namba, Jun Hirano, Hiroshi Tanaka, Mitsuhiro Takenoyama, Toshiaki Takahashi, Satoshi Oizumi, Fumio Imamura, Kuninobu Kanai, Toyoaki Hida, Yuichiro Takeda, Kazuhiko Nakagawa, Nobukazu Fujimoto, Terufumi Kato, Keisuke Aoe, Takashi Kijima, Morihito Okada
Criteria for discontinuation of nivolumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29ecdfef4a2438b96568eeb37ae73449
https://doi.org/10.1158/1078-0432.22471298.v1
https://doi.org/10.1158/1078-0432.22471298.v1
Autor:
Yuichiro Ohe, Yoshinobu Namba, Jun Hirano, Hiroshi Tanaka, Mitsuhiro Takenoyama, Toshiaki Takahashi, Satoshi Oizumi, Fumio Imamura, Kuninobu Kanai, Toyoaki Hida, Yuichiro Takeda, Kazuhiko Nakagawa, Nobukazu Fujimoto, Terufumi Kato, Keisuke Aoe, Takashi Kijima, Morihito Okada
Kaplan-Meier curves for overall survival (A) and progressionfree survival (B) for all patients according tumor type (epithelioid and non-epithelioid subtypes)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5118aba423ec04cf8abe0e7dc030672c
https://doi.org/10.1158/1078-0432.22471304
https://doi.org/10.1158/1078-0432.22471304
Autor:
Hisamori Kato, Nobuhiro Takeshima, Noriyuki Katsumata, Takayuki Enomoto, Hidemichi Watari, Yusuke Takahashi, Junzo Hamanishi, Takashi Matsumoto, Koji Matsumoto, Kimio Ushijima, Kazuhiro Takehara, Hidekatsu Nakai, Ikuo Konishi, Takashi Sawasaki, Toru Sugiyama, Masaki Mandai, Satoshi Takeuchi, Akira Takazawa, Kimihiko Ito, Eiji Kondo, Yoichi Aoki, Noriaki Sakuragi, Satomi Aihara, Hiroshi Kobayashi, Toshiaki Saito, Aikou Okamoto, Daisuke Aoki, Nobutaka Takahashi, Kosei Hasegawa, Satoru Nagase, Yoshinobu Namba, Tadashi Kimura, Mika Mizuno, Kan Yonemori, Yoshito Terai, Keiichi Fujiwara, Hitoshi Niikura, Kenzo Sonoda, Nao Suzuki, Hirokuni Takano, Sari Nakao, Hidenori Kato
Publikováno v:
Journal of Clinical Oncology. 39(33):3671-3681
PURPOSE This phase III, multicenter, randomized, open-label study investigated the efficacy and safety of nivolumab versus chemotherapy (gemcitabine [GEM] or pegylated liposomal doxorubicin [PLD]) in patients with platinum-resistant ovarian cancer. M
Autor:
Takashi Kijima, Hiroshi Tanaka, Kazuhiko Nakagawa, Keisuke Aoe, Mitsuhiro Takenoyama, Morihito Okada, Toshiaki Takahashi, Yuichiro Ohe, Yuichiro Takeda, Toyoaki Hida, Terufumi Kato, Yoshinobu Namba, Fumio Imamura, Satoshi Oizumi, Jun Hirano, Kuninobu Kanai, Nobukazu Fujimoto
Publikováno v:
Clinical Cancer Research. 25:5485-5492
Purpose: Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy with poor prognosis. Patients with MPM who do not respond to standard first-line chemotherapy have limited treatment options. We evaluated the efficacy and safety of ni
Autor:
Hironobu Minami, Suguru Asada, Hiroshi Uchi, Naoya Yamazaki, Hisashi Uhara, Masahiro Hatsumichi, Yoshio Kiyohara, Hiroshi Koga, Kenjiro Namikawa, Sumiko Takatsuka, Yoshinobu Namba, Naoko Wada, Shusuke Yoshikawa, Tatsuya Takenouchi
Publikováno v:
European Journal of Cancer. 105:114-126
Aim The aim of the study was to evaluate the efficacy and safety of nivolumab combined with ipilimumab in treatment-naive Japanese patients with advanced melanoma. Methods In this multicentre, single-arm study, treatment-naive Japanese patients with
Autor:
Hiroaki Akamatsu, Kazuhiko Nakagawa, Shunichi Sugawara, Hiroshi Tanaka, N. Sumiyoshi, Teruhiko Yoshida, C. Yu, Nobuyuki Yamamoto, Yuichiro Ohe, J.H. Kang, N. Inui, M. Nishio, Toyoaki Hida, Yoshinobu Namba, K.H. Lee, Jung-Gon Lee, H.R. Kim, C.-T. Yang, Tomohide Tamura
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 32(9)
This international, randomized, double-blind phase III study (ONO-4538-52/TASUKI-52) evaluated nivolumab with bevacizumab and cytotoxic chemotherapy as first-line treatment for nonsquamous non-small-cell lung cancer (NSCLC).Between June 2017 and July
Autor:
Hisashi Uhara, Naoko Wada, Naoya Yamazaki, Yoshio Kiyohara, Hiroshi Uchi, Hiroshi Koga, Shusuke Yoshikawa, Tatsuya Takenouchi, Sumiko Takatsuka, Masahiro Hatsumichi, Hironobu Minami, Kenjiro Namikawa, Yoshinobu Namba
Publikováno v:
The Journal of Dermatology
Nivolumab plus ipilimumab combination is currently one of the preferred regimens for advanced melanoma in recently updated clinical practice guidelines. However, the evidence on the efficacy of the combination for acral or mucosal subtypes remains le
Autor:
Yoichi Nakanishi, Shiro Fujita, Masashi Takahashi, Terufumi Kato, Toyoaki Hida, Tomohide Tamura, Noriyuki Masuda, Koji Takeda, Yoshinobu Namba, Shinji Atagi, Hiroshi Tanaka, Miyako Satouchi, Hiroshi Sakai
Publikováno v:
Lung Cancer. 104:111-118
Objectives Drug-induced interstitial lung disease (ILD) is often associated with high mortality; however it is difficult to predict and manage. we examined the clinical findings and imaging characteristics of nivolumab induced ILD reported in the two
Autor:
Yuichiro Ohe, Yoshinobu Namba, Hiroshi Tanaka, Tomohide Tamura, H.R. Kim, M. Nishio, Nobuyuki Yamamoto, Toyoaki Hida, Teruhiko Yoshida, Shunichi Sugawara, K.H. Lee, C.-T. Yang, N. Inui, Kazuhiko Nakagawa, J-S. Lee, C. Yu, Hiroaki Akamatsu, J.H. Kang, N. Sumiyoshi
Publikováno v:
Annals of Oncology. 31:S1184-S1185